Primary Intraspinal Neuroendocrine Tumor: A Case Report and Literature Review

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2024 Aug 9

PMID 39121254

Authors

Li Dai

Ming-Ju Zou

Ren-Li Liao

Bing-Ran Zhang

Zhi-Qiang Ma

Ming-Wei Liu

Affiliations

Soon will be listed here.

Abstract

Rationale: Neuroendocrine tumors (NET) refer to a group of uncommon tumors arising in the neuroendocrine system. Most NETs occur in the digestive tract and bronchi but are rare in the central nervous system, especially in the spinal canal. NET in the central nervous system mainly metastasize from other systems, with non-specific clinical symptoms. In this study, we report the diagnosis and treatment of intraspinal NET to provide clinical guidance as well as to avoid misdiagnosis and missed diagnosis.

Patient Concerns: A 59-year-old male patient, presented with recurrent right lower limb pain for half a year, accompanied by numbness and weakness for 4 months and aggravation for 2 months. Lumbar spine magnetic resonance imaging (MRI) revealed a space-occupying lesion in the spinal canal. The diagnosis of primary intraspinal NET was confirmed by topathological examination.

Diagnosis: Primary intraspinal NET tumor.

Interventions: Surgical resection.

Outcomes: Significant improvements in right lower limb pain, numbness, and weakness were observed, and lumbar spine MRI was performed again to dynamically observe the changes in intraspinal NET.

Conclusions: Surgical resection may be an effective treatment for intraspinal NETs.

Lessons: Intraspinal NETs are relatively rare and mostly manifest as limb numbness, weakness, and pain. Due to its nonspecific clinical symptoms, intraspinal NETs are easily misdiagnosed as lumbar disc herniation with radiculopathy and lumbar spondylolisthesis. Therefore, in patients with long-term symptoms, in addition to common lumbar neuromuscular diseases, lumbar MRI should be performed promptly to exclude the possibility of lumbar NETs.

References

Das S, Al-Toubah T, El-Haddad G, Strosberg J . Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors. Expert Rev Gastroenterol Hepatol. 2019; 13(11):1023-1031. PMC: 7227421. DOI: 10.1080/17474124.2019.1685381. View

Xia L, Tang J, Huang S . Primary intraspinal benign tumors treated surgically: an analysis from China. Br J Neurosurg. 2021; 35(5):603-606. DOI: 10.1080/02688697.2021.1923648. View

Djokic M, Hadzialjevic B, Rankovic B, Dezman R, Tomazic A . Neuroendocrine Tumor Arising within Mature Cystic Teratoma of the Pancreas: Literature Review and Case Report. Curr Oncol. 2022; 29(7):4717-4724. PMC: 9322391. DOI: 10.3390/curroncol29070374. View

Kasajima A, Kloppel G . Neuroendocrine tumor G3 of bronchopulmonary origin and its classification. Pathol Int. 2022; 72(10):488-495. DOI: 10.1111/pin.13266. View

Bian Y, Li J, Jiang H, Fang X, Cao K, Ma C . Tumor Size on Microscopy, CT, and MRI Assessments Versus Pathologic Gross Specimen Analysis of Pancreatic Neuroendocrine Tumors. AJR Am J Roentgenol. 2021; 217(1):107-116. DOI: 10.2214/AJR.20.23413. View

ODorisio T, Harris A, ODorisio M . Evolution of Neuroendocrine Tumor Therapy. Surg Oncol Clin N Am. 2020; 29(2):145-163. PMC: 7702714. DOI: 10.1016/j.soc.2019.11.002. View

Szidonya L, Park E, Kwak J, Mallak N . Molecular and Anatomic Imaging of Neuroendocrine Tumors. Surg Oncol Clin N Am. 2022; 31(4):649-671. DOI: 10.1016/j.soc.2022.06.009. View

Nagel S, Hughes G, Ugokwe K, Prayson R, Krishnaney A . Spinal carcinoid metastasis with dural invasion. World Neurosurg. 2011; 76(5):478.e7-478.e11. DOI: 10.1016/j.wneu.2010.10.045. View

Wei X, Zhang X, Song Z, Wang F . Analysis of Clinical, Imaging, and Pathologic Features of 36 Patients with Primary Intraspinal Primitive Neuroectodermal Tumors: A Case Series and Literature Review. J Neurol Surg A Cent Eur Neurosurg. 2021; 82(6):526-537. DOI: 10.1055/s-0041-1723810. View

10.

Sheikhbahaei S, Sadaghiani M, Rowe S, Solnes L . Neuroendocrine Tumor Theranostics: An Update and Emerging Applications in Clinical Practice. AJR Am J Roentgenol. 2021; 217(2):495-506. DOI: 10.2214/AJR.20.23349. View

11.

Duan H, Iagaru A . Neuroendocrine Tumor Diagnosis: PET/MR Imaging. PET Clin. 2023; 18(2):259-266. DOI: 10.1016/j.cpet.2022.11.008. View

12.

Nathoo N, Mendel E . Spinal carcinoid metastasis: rare but important differential diagnosis of a spinal mass. World Neurosurg. 2011; 76(5):415-6. DOI: 10.1016/j.wneu.2010.11.023. View

13.

Ito T, Lee L, Jensen R . Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies. Expert Opin Pharmacother. 2016; 17(16):2191-2205. PMC: 5545682. DOI: 10.1080/14656566.2016.1236916. View

14.

Yao J, Hassan M, Phan A, Dagohoy C, Leary C, Mares J . One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008; 26(18):3063-72. DOI: 10.1200/JCO.2007.15.4377. View

15.

Tsimpas A, Post N, Moshel Y, Frempong-Boadu A . Large cell neuroendocrine carcinoma of the lung metastatic to the cauda equina. Spine J. 2010; 10(6):e1-5. DOI: 10.1016/j.spinee.2010.03.031. View

16.

Vitale G, Carra S, Alessi Y, Campolo F, Pandozzi C, Zanata I . Carcinoid Syndrome: Preclinical Models and Future Therapeutic Strategies. Int J Mol Sci. 2023; 24(4). PMC: 9961914. DOI: 10.3390/ijms24043610. View